Jazz Pharmaceuticals
JAZZ • NASDAQ
Jazz Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Renee D. Gala, with a market cap of $11.2B.
CEORenee D. Gala
Next Earnings
Upcoming earnings announcement for Jazz Pharmaceuticals
Date
Tuesday, May 5, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$4.36
Revenue Estimate
$978.4M
Earnings History
Past 12 earnings reports for Jazz Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 24, 2026 | Q4 2025 | $6.64Est: $6.16 | +7.8% | $1.2BEst: $1.2B | +2.2% |  10-K |
| Nov 5, 2025 | Q3 2025 | $8.13Est: $5.43 | +49.7% | $1.1BEst: $1.1B | +1.9% | 10-Q |
| Aug 5, 2025 | Q2 2025 | -$8.25Est: -$6.34 | -30.1% | $1.0BEst: $1.0B | -0.2% | 10-Q |
| May 6, 2025 | Q1 2025 | $1.68Est: $4.66 | -63.9% | $897.8MEst: $983.8M | -8.7% | 10-Q |
| Feb 25, 2025 | Q4 2024 | $6.60Est: $5.81 | +13.6% | $1.1BEst: $1.1B | +2.6% | 10-K/A |
| Nov 6, 2024 | Q3 2024 | $6.61Est: $5.50 | +20.2% | $1.1BEst: $1.0B | +1.4% | 10-Q |
| Jul 31, 2024 | Q2 2024 | $5.30Est: $4.80 | +10.4% | $1.0BEst: $1.0B | +1.4% | 10-Q |
| May 1, 2024 | Q1 2024 | $2.68Est: $4.18 | -35.9% | $902.0MEst: $953.9M | -5.4% | 10-Q |
| Feb 28, 2024 | Q4 2023 | $5.02Est: $5.16 | -2.7% | $1.0BEst: $1.0B | +0.2% | 10-K/A |
| Nov 8, 2023 | Q3 2023 | $4.84Est: $4.91 | -1.4% | $972.1MEst: $965.7M | +0.7% | — |
| Aug 9, 2023 | Q2 2023 | $4.51Est: $4.43 | +1.8% | $957.3MEst: $942.9M | +1.5% | — |
| May 10, 2023 | Q1 2023 | $3.95Est: $4.24 | -6.8% | $892.8MEst: $895.4M | -0.3% | — |